Notable analyst calls this week: Broadcom, Moderna and Abbott among top picks

What happened

D.A. Davidson upgraded Broadcom to Buy from Neutral and raised its price target to $400 from $350. William Blair downgraded Moderna to Market Perform from Outperform, citing valuation concerns after the stock rose 545% year-to-date following positive trial news for its cancer shot with Merck.

Confirmed

Global impact / market context

Analyst rating changes can shift investor demand for a stock. The Broadcom upgrade signals expectations that future capital raising by AI companies could support its business. The Moderna downgrade warns that sharp price gains may already reflect good news, which means future upside could be limited.

Analyst inference

The S&P 500 closed lower on Friday as investors weighed corporate results from Alphabet and Microsoft. In this setting, analysts issued fresh upgrades and downgrades. Broadcom was framed as a way to gain exposure to AI-related capital raising, while Moderna's large yearly gain prompted caution on valuation, which means its price relative to expected earnings.

Analyst inference

What to watch

1. D.A. Davidson set a $400 price target on Broadcom, up from $350, and moved its rating to Buy. The analyst tied the view to expected capital raising by Anthropic and OpenAI. Confirmed
2. Watch whether Anthropic proceeds with its IPO and raises capital, and whether OpenAI follows with its own IPO. The analyst said these deals would help Broadcom meet expectations over the next couple of years. Proposed
3. Watch Moderna's valuation after its 545% year-to-date rise. If upcoming trial results or Merck-partnered cancer shot updates disappoint, the stock could fall because good news may already be priced in. Analyst inference

Evidence

• seekingalpha.com